Investigating genetic factors in severe infections
Genetic Susceptibility to Severe Infections Including in Particular but Not Exhaustively All Types of Viral, Bacterialn and Fungal Infections.
This study is trying to find out if certain genes make some people more likely to get severe infections than others by looking at patients with rare and serious infections.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 1 site (Paris, Île-de-France Region) |
| Trial ID | NCT06102070 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the genetic susceptibility of individuals to severe infections by examining the interplay between genetic and environmental factors that influence immune responses. It will involve recruiting patients with rare and severe infections, focusing on those requiring hospitalization or experiencing chronic infections. Blood samples and skin biopsies will be collected to analyze the underlying genetic factors contributing to these infections. The study seeks to enhance understanding of why some individuals develop severe disease while others do not.
Who should consider this trial
Good fit: Ideal candidates include individuals with proven rare and severe infections who are hospitalized or followed in specialized medical settings.
Not a fit: Patients with acquired immunodeficiency or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved identification of individuals at risk for severe infections and inform targeted prevention strategies.
How similar studies have performed: While the investigation of genetic susceptibility to infections has been explored, this specific approach focusing on rare infections is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * to sign the informed consent signed by the patient. In the case of a minor patient, consent is signed by the holders of parental authority. In the case of a protected adult patient, the consent is signed by their legal representative. In the case of an adult patient unable to consent at the time of inclusion, consent is signed by a family member. * to have a proven rare and severe infection * to be hospitalized or followed in a specialized hospital department, in the emergency room or in intensive care * to be affiliated to the French Social Security system * for relatives, to be related to the index case up to the 3rd degree: Parents, Children, Brother, Sister, Grandparents, Uncles, Aunts, Cousins, Nephews, Nieces Exclusion Criteria * to have an acquired immunodeficiency (having received immunosuppressive treatment in the 3 months preceding the onset of the disease or being HIV positive) * pregnant woman at the time of illness
Where this trial is running
Paris, Île-de-France Region
- Centre d'Etudes des Déficits Immunitaires (CEDI), Hôpital Necker-Enfants — Paris, Île-de-France Region, France (Recruiting)
Study contacts
- Study coordinator: Jacinta Md BUSTAMANTE, MD-PhD
- Email: jacinta.bustamante@aphp.fr
- Phone: 01 71 19 60 04
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.